What has the higher NICE threshold meant for patients?
The NICE cost-effectiveness threshold is a key factor in whether the NHS makes new medicines available to patients. It is the yardstick used to decide whether a medicine is value for money for the NHS. In April 2026, for the first time in over twenty years, the threshold was increased from £20,000 - £30,000 to £25,000 - £35,000.
The government’s decision to make this historic change captured multiple objectives, including improving UK patient access to innovative medicines, supporting industrial policy, economic growth and investment, while retaining NICE’s independent, evidence-based decision-making.
The decision is critical to turning around decades of underinvestment in medicines and helping patients across many disease areas access innovative medicines in a timely way.
The ABPI’s latest Continuous NICE Implementation Evaluation (CONNIE) report examines some of these positive outcomes. The early signs are encouraging: more than 15,400 additional patients a year could now benefit from innovative medicines that may not otherwise have been available to them.
What has been the impact on access decisions?
Twenty submissions to CONNIE had a guidance publication date after the threshold was increased. These covered a period from 1 April to 5 August and included 63 per cent of appraisals published by NICE during this time.
In 10 of them (half), companies reported that the threshold change had enabled patient access. In one case, it allowed access to be extended to a wider group of patients than would have been possible under the previous threshold.
In the other nine, the company considered that the committee may not have made a positive recommendation at the previous threshold.
Six of the companies reported they would not have been able to launch their medicine under the previous threshold.
Which patients are benefiting?
Based on company estimates of eligible patients, the 10 positively affected appraisals could benefit an additional 15,426 patients a year. For each of those patients and their families, access to a new treatment can mean more time, better quality of life and greater independence.
These approvals span a range of serious and life-limiting conditions. Seven of the 10 medicines were for cancer patients - including brain tumours that could affect young children, late-stage breast cancer, and advanced stomach cancers for people with limited treatment options. Two were for cardiovascular conditions, and one was for an endocrine condition.
What the findings can and cannot tell us
These are early results, and several important factors should be considered.
A key limitation is that CONNIE does not include data on every NICE appraisal, so it did not capture some appraisals affected by the threshold increase.
Cross-comparison with the nine indications reported by government as having benefitted from the threshold increase indicated that CONNIE captured eight of these, so the number of medicines now available to patients because of the threshold increase is at least 11.
Finally, the period covered may not reflect the new normal. The threshold change was introduced alongside interim arrangements, including a pause in appraisals where the threshold increase could enable a positive recommendation. As the new threshold is embedded, the pattern of decisions may shift.
Looking ahead
Early evidence clearly shows that the threshold increase is helping patients access medicines they might otherwise have gone without. Bringing the threshold closer to comparable countries, after two decades of stagnation, means patients in the UK are better placed to benefit from the medicines our industry is developing.
The task now is to ensure the benefits continue to be observed and reach patients with all types of conditions. The ABPI will keep tracking the impact through our CONNIE platform and working with NICE, government and the NHS to make that happen.
Last reviewed date: 19 November 2026
Next review date: 19 November 2029